A biomarker of meningioma recurrence has the potential to shape personalized medicine approaches in the future by allowing clinicians to match the extent of initial meningioma treatment to the risk for later recurrence based on the presence or absence of a GSTM1 null genotype. The gene discussed is GSTM1; the disease is meningioma.